顧みられない熱帯病治療薬・ワクチンの世界市場規模：製品別、疾患別、地域範囲別、予測

顧みられない熱帯病治療薬・ワクチンの市場規模と予測

顧みられない熱帯病（Neglected Tropical Diseases：NTD）治療薬・ワクチン市場規模は、ここ数年大幅な成長率で緩やかなペースで成長しており、市場推計・予測期間（2026年～2032年）には大きく成長すると予測されます。

• 顧みられない熱帯病（Neglected Tropical Diseases：NTD）治療薬・ワクチンは、主に熱帯・亜熱帯地域の人々が罹患し、医療資源へのアクセスが限られている疾病を予防、治療、根絶するために特別に設計された医薬品と予防接種です。
• マラリア、デング熱、リーシュマニア症、住血吸虫症は、世界中で数百万人が罹患している病気のひとつであり、その大半は低所得国に住んでいます。
• NTD治療薬は、多くの病原体による感染症を治療するためのものであり、ワクチンは免疫系を活性化し、これらの疾患の発症を予防しようとするものです。
• さらに、これらの治療法は、著名な感染症に比べ、一般的に注目度や資金が低い疾病を対象とすることで、世界ヘルス構想において重要な役割を果たしており、それにより、世界規模での健康格差の是正と医療アクセスの公平性を促進しています。

顧みられない熱帯病治療薬・ワクチンの世界市場力学

顧みられない熱帯病治療薬・ワクチン市場を形成している主な市場力学は以下の通りです：

主な市場促進要因

• 世界保健イニシアティブと資金調達の増加：WHO、ゲイツ財団、その他の非政府組織が主導する世界保健イニシアティブは、NTDの研究開発への資金提供や支援を拡大しています。このような支援は、必要な治療やワクチンを供給することで、特定の疾病の撲滅や制圧を目指すものであり、市場を牽引しています。
• 研究開発における技術の進歩：バイオテクノロジーと遺伝学の進歩により、NTDsの治療法やワクチンの発見が加速しています。高度な技術の利用は、新たな治療法やワクチンの発見を加速させ、市場の成長を後押ししています。
• 意識の高まりと政府の支援：NTDsに対する世界の認識が高まり、NTDsと闘うための政府や国際的な支援が増加しています。NTDの予防、管理、撲滅を目的とした国家保健プログラムや政策が、実行可能な治療ソリューションの必要性を促進しています。
• 協力とパートナーシップ：政府、製薬企業、非営利団体間の戦略的提携は、NTD治療とワクチンの開発・提供に不可欠です。こうした提携により、調査、資金調達、治療がより利用しやすくなり、市場成長に大きく貢献します。

主な課題

• 製薬会社に対する経済的インセンティブの制限：顧みられない熱帯病（Neglected Tropical Diseases）は、主に低開発国の低所得者層を対象としているため、製薬企業が研究開発に投資する商業的インセンティブはほとんどないです。このような資金的動機の欠如が、革新的で効果的な医薬品の開発を妨げています。
• 複雑な医薬品開発プロセス：NTDsの治療薬やワクチンの開発プロセスは複雑で、費用と時間がかかります。課題には、大規模な臨床研究の必要性、規制当局の承認、これらの疾病の影響を最も受ける地域での調査の難しさなどがあり、これらすべてが市場成長に影響を与えます。
• 流通とアクセスの課題：遠隔地や貧困地域での効果的な医薬品やワクチンの流通は大きな懸念事項です。貧弱なインフラ、ヘルスケア施設の不足、政情不安により、治療を必要とする人々が治療にアクセスできず、利用可能な解決策の有効性が制限されます。

主要動向：

• 官民パートナーシップ（PPP）の利用拡大：政府、民間企業、非営利団体間の協力が増加しています。このような協力関係は、NTD治療薬やワクチンの資金調達、研究、流通を促進し、市場の成長と支援活動を向上させるために、各セクターの強みを活かしています。
• ワクチン開発に焦点を当てる：ワクチンの予防的性質と費用対効果を考慮し、NTDワクチンの研究が重視されつつあります。mRNAワクチンや遺伝子組換えワクチンなど、ワクチン技術における革新が、これらの疾患を予防するために研究されており、この分野における大きな動向を示しています。
• 世界ヘルスへの取り組みによるアクセスの拡大：世界ヘルスプログラムは、NTD治療やワクチン接種へのアクセス改善にますます力を注いでいます。NTDsの世界の負担を最小化するため、コスト削減交渉、サプライチェーンの強化、感染地域のヘルスケア施設の改善に向けた取り組みが行われており、市場力学の形成につながるであろう。

目次

第1章 顧みられない熱帯病治療薬・ワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 顧みられない熱帯病治療薬・ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 顧みられない熱帯病治療薬・ワクチンの世界市場：製品別

• 概要
• 医薬品
• ワクチン

第6章 顧みられない熱帯病治療薬・ワクチンの世界市場：疾患別

• 概要
• リンパ系フィラリア症
• エキノコックス症
• リーシュマニア症
• ドラクンカ症
• デング熱
• チクングニア
• その他

第7章 顧みられない熱帯病治療薬・ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 顧みられない熱帯病治療薬・ワクチンの世界市場競争情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Johnson & Johnson
• GlaxoSmithKline
• Sanofi
• Novartis
• Bayer
• Eli Lilly and Company
• Pfizer
• AbbVie Inc.
• Amgen Inc.
• Gilead Sciences Inc.

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Neglected Tropical Diseases Drugs And Vaccines Market Size And Forecast

The Neglected Tropical Diseases Drugs And Vaccines Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e.2026 to 2032.

• Neglected Tropical Diseases (NTD) Drugs and vaccines are pharmaceuticals and vaccinations specifically designed to prevent, treat, or eradicate diseases that primarily affect populations in tropical and subtropical regions with limited access to healthcare resources.
• Malaria, dengue fever, leishmaniasis, and schistosomiasis are among the diseases that affect millions of people globally, with the majority of them living in low-income nations.
• NTD medicines are intended to treat infections caused by numerous pathogens, whilst vaccines attempt to activate the immune system and prevent the onset of these diseases.
• Furthermore, these interventions play an important role in global health initiatives by targeting diseases that generally receive less attention and financing than more prominent infectious diseases, thereby reducing health inequities and promoting fairness in healthcare access on a worldwide scale.

Global Neglected Tropical Diseases Drugs And Vaccines Market Dynamics

The key market dynamics that are shaping the Neglected Tropical Diseases Drugs And Vaccines Market include:

Key Market Drivers

• Increased Global Health Initiatives and Funding: Global health initiatives led by WHO, the Gates Foundation, and other non-governmental organizations have expanded financing and support for NTD research and development. This support seeks to eliminate or control certain diseases by supplying required treatments and vaccines, hence driving the market.
• Technological Advancements in Research and Development: Advances in biotechnology and genetics have accelerated the discovery of treatments and vaccines for NTDs. The use of advanced techniques accelerates the discovery of novel treatment approaches and vaccines, driving market growth.
• Rising Awareness and Government Support: There is an increasing global awareness of NTDs, which has led to increased government and international assistance for combating these diseases. National health programs and policies aimed at NTD prevention, control, and elimination promote the need for viable treatment solutions.
• Collaborations and Partnerships: Strategic alliances among governments, pharmaceutical corporations, and non-profit groups are critical for the development and delivery of NTD treatments and vaccines. These alliances make research, funding, and therapy more accessible, hence contributing considerably to market growth.

Key Challenges:

• Limited Financial Incentives for Pharmaceutical Companies: Neglected Tropical Diseases primarily affect low-income populations in underdeveloped nations, providing few commercial incentives for pharmaceutical corporations to invest in R&D. This lack of financial motive hampers the development of innovative and effective medicines.
• Complex Drug Development Process: The drug and vaccine development process for NTDs is complicated, expensive, and time-consuming. Challenges include the requirement for extensive clinical studies, regulatory approvals, and the difficulty of doing research in the regions most impacted by these diseases, all of which impact market growth.
• Distribution and Access Challenges: Effective medicine and vaccine distribution in remote and poor locations is a major concern. Poor infrastructure, a lack of healthcare facilities, and political instability make treatments inaccessible to individuals in need, limiting the effectiveness of available solutions.

Key Trends:

• Increased Use of Public-Private Partnerships (PPPs): Collaborations between governments, commercial sector entities, and non-profit groups are increasing. These collaborations use the strengths of each sector to increase funding, research, and distribution efforts for NTD medications and vaccines, hence improving market growth and outreach.
• Focus on Vaccine Development: Given vaccines' preventive nature and cost-effectiveness, there is a growing emphasis on NTD vaccine research. Innovations in vaccine technology, such as mRNA and recombinant vaccines, are being investigated to prevent these diseases, indicating a significant trend in the field.
• Expanding Access Through Global Health Initiatives: Global health programs are increasingly focusing on improving access to NTD treatments and vaccinations. Efforts to negotiate lower costs, strengthen supply chains, and improve healthcare facilities in impacted areas aim to minimize the worldwide burden of NTDs, which will shape market dynamics.

Global Neglected Tropical Diseases Drugs And Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Neglected Tropical Diseases Drugs And Vaccines Market:

Asia Pacific:

• According to VMR Analyst, Asia Pacific is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market during the forecast period. A large proportion of the global population is affected by Neglected Tropical Diseases (NTDs) in Asia Pacific. The high prevalence of these diseases in the region generates a need for effective treatments and vaccines, establishing Asia Pacific as a critical market for NTD therapies.
• Governments and private sectors in the Asia-Pacific region are investing more in healthcare infrastructure and services. This includes major investment in NTD prevention, treatment, and eradication, which will help to boost the region's medication and vaccine markets.
• The region has emerged as a hotspot for collaborative R&D initiatives aimed at NTDs, with partnerships comprising local governments, international health organizations, and pharmaceutical corporations. These agreements improve the development and availability of new therapies and vaccinations.
• Furthermore, in Asia Pacific countries, improvements in healthcare access and delivery systems have made it easier to distribute and administer NTD treatments and vaccines. Enhanced healthcare infrastructure and higher healthcare spending help to explain the region's dominance in the NTD medicines and vaccines market.

Latin America:

• In Latin America, governments and non-governmental organizations (NGOs) have launched comprehensive efforts to control and eliminate NTDs. These initiatives include mass drug administration campaigns and vaccination drives, which have considerably increased the demand for NTD-related pharmaceuticals and vaccines in the region.
• Latin America benefits from international financing and cooperation to tackle NTDs. Global health organizations such as PAHO, WHO, and the Gates Foundation provide critical financial and technical support for medicine and vaccine research, development, and distribution, hence boosting market growth.
• Latin America has experienced a surge in regional collaboration on NTD research and development. Consortia of local research institutions, universities, and pharmaceutical businesses are developing creative methods to combat NTDs, promoting local market growth.
• Furthermore, the region's healthcare infrastructure and services are improving significantly, making it easier to deliver NTD treatments and vaccines. Improved healthcare systems, as well as increased healthcare access in rural and underprivileged areas, are significant drivers of Latin America's growing market for NTD interventions.

Middle East & Africa:

• Due to socioeconomic and climatic variables, the Middle East and Africa (MEA) region has a high incidence of neglected tropical diseases. The high prevalence of NTDs creates an urgent need for effective medications and vaccines, accelerating market growth in this region.
• MEA governments, with the backing of international health organizations, are increasingly focused on NTD control and elimination programs. These activities frequently include mass drug administration and immunization campaigns, which directly increase demand for NTD-related drugs.
• Healthcare investments in the MEA region have increased significantly, with an emphasis on enhancing infrastructure and access. This includes investments in hospitals, clinics, and distribution networks for medications and vaccinations, which will expand the reach and impact of NTD interventions.
• Furthermore, MEA countries and worldwide partners are collaborating to promote NTD research and development. These collaborations seek to develop and implement effective treatments and vaccinations adapted to the region's specific needs, hence promoting the growth of the NTD medications and vaccines market.

Global Neglected Tropical Diseases Drugs And Vaccines Market: Segmentation Analysis

The Global Neglected Tropical Diseases Drugs And Vaccines Market is segmented based on Product, Disease, And Geography.

Neglected Tropical Diseases Drugs And Vaccines Market, By Product

• Drugs
• Vaccines

Based on Product, the market is segmented into Drugs and Vaccines. The drugs segment is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market due to the acute requirement for therapy in affected people, medications are the primary intervention approach. Drugs are utilized not only for treatment but also for preventative chemotherapy in high-risk populations, which can be implemented faster than vaccine development and distribution. Furthermore, the wider choice of accessible pharmacological therapies for numerous NTDs, as opposed to vaccinations, which are only available for a few diseases, contributes to pharmaceuticals' bigger market share.

Neglected Tropical Diseases Drugs And Vaccines Market, By Disease

• Lymphatic Filariasis
• Echinococcosis
• Leishmaniasis
• Dracunculiasis
• Dengue
• Chikungunya
• Others

Based on Disease, the market is segmented into Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya, and Others. The Dengue disease segment is estimated to hold the majority share in the forecast period in the Neglected Tropical Diseases Drugs And Vaccines Market owing to dengue fever's extensive prevalence in tropical and subtropical locations around the world, which affects millions of people each year. The disease's high occurrence rate, combined with the serious health issues it can bring, necessitates extensive research and development efforts for effective dengue vaccines and therapeutic medications. Furthermore, increasing public health initiatives and financing targeted at preventing dengue transmission, such as large-scale vaccination campaigns and community awareness programs, add to the need for dengue-related pharmaceutical products.

Key Players

• The "Neglected Tropical Diseases Drugs And Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Sanofi, Merck & Co., Novartis, Bayer, Eli Lilly and Company, Pfizer, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Roche Diagnostics International Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Neglected Tropical Diseases Drugs And Vaccines Market Recent Developments
• In March 2024, the World Health Organization (WHO) emphasized African health ministers' commitment to eliminating malaria deaths. This represents a larger effort to control diseases that frequently overlap with neglected tropical diseases, even if it is not a direct NTD medicine or vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Drugs
• 5.3 Vaccines

6 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY DISEASE

• 6.1 Overview
• 6.2 Lymphatic Filariasis
• 6.3 Echinococcosis
• 6.4 Leishmaniasis
• 6.5 Dracunculiasis
• 6.6 Dengue
• 6.7 Chikungunya
• 6.8 Others

7 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Johnson & Johnson
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 GlaxoSmithKline
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Sanofi
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Novartis
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Bayer
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Eli Lilly and Company
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Pfizer
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 AbbVie Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Amgen Inc.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Gilead Sciences Inc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research